A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects with Advanced or Recurrent Tumors.
Phase of Trial: Phase I/II
Latest Information Update: 14 Sep 2017
At a glance
- Drugs RGT 100 (Primary) ; RGT 100 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Rigontec
- 03 May 2017 According to a Rigontec media release, first patient has been dosed in the study.
- 11 Apr 2017 Planned End Date changed from 1 Sep 2018 to 1 Dec 2019.
- 11 Apr 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2019.